PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.
The main drivers of growth include the rapid uptake of new MS DMTs, especially oral therapies, and DMTs that specifically target the high proportion of MS patients who have progressive MS subtypes. However, with Germany being the second largest generics market worldwide, the potential future market size is limited by the patent expiries of several key branded drugs, which will result in rapid generic erosion. In addition, strict government pricing restrictions could also hamper the growth of the market by limiting the pricing and penetration of new DMTs.
Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Germany from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Germany Multiple Sclerosis market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Germany